Exagen (NASDAQ:XGN) Releases FY 2021 Earnings Guidance

Exagen (NASDAQ:XGN) updated its FY 2021 earnings guidance on Tuesday. The company provided earnings per share guidance of $- for the period. The company issued revenue guidance of $47 million-49 million, compared to the consensus revenue estimate of $47.99 million.

A number of brokerages have issued reports on XGN. KeyCorp lifted their price objective on Exagen from $32.00 to $33.00 and gave the company an overweight rating in a report on Tuesday, March 2nd. Zacks Investment Research cut Exagen from a hold rating to a sell rating in a report on Saturday, March 20th. Canaccord Genuity started coverage on Exagen in a report on Thursday, April 15th. They issued a buy rating and a $25.00 price target for the company. Cowen lifted their price target on Exagen from $21.00 to $26.00 and gave the company an outperform rating in a report on Wednesday, March 17th. Finally, TheStreet lowered Exagen from a c- rating to a d rating in a research report on Tuesday, March 23rd. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company has an average rating of Buy and an average target price of $23.20.

Shares of XGN opened at $15.40 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 16.41 and a quick ratio of 16.41. The company has a 50 day simple moving average of $15.19. Exagen has a 52-week low of $10.29 and a 52-week high of $24.67. The firm has a market cap of $260.69 million, a price-to-earnings ratio of -11.32 and a beta of 0.49.

Exagen (NASDAQ:XGN) last issued its quarterly earnings data on Tuesday, May 11th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.02). The business had revenue of $10.59 million during the quarter, compared to analyst estimates of $10.24 million. Exagen had a negative net margin of 40.33% and a negative return on equity of 29.42%. As a group, research analysts anticipate that Exagen will post -1.82 EPS for the current fiscal year.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States. It enables rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

Further Reading: What is the QQQ ETF?

Earnings History and Estimates for Exagen (NASDAQ:XGN)

Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.